Buscar
Disc Medicine Inc
IRONAñadir a la lista de seguimiento
66.860USD
-2.840-4.07%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
2.55BCap. mercado
PérdidaP/E TTM
Más Datos de Disc Medicine Inc Compañía
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Información de Disc Medicine Inc
Símbolo de cotizaciónIRON
Nombre de la empresaDisc Medicine Inc
Fecha de salida a bolsaAug 12, 2020
Director ejecutivoQuisel (John D)
Número de empleados84
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 12
Dirección321 Arsenal Street, Suite 101
CiudadWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Teléfono16176749274
Sitio Webhttps://www.discmedicine.com/
Símbolo de cotizaciónIRON
Fecha de salida a bolsaAug 12, 2020
Director ejecutivoQuisel (John D)
Ejecutivos de Disc Medicine Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
51.02K
+27.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
18.66K
+6.25%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark Chin
Mr. Mark Chin
Independent Director
Independent Director
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
51.02K
+27.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
18.66K
+6.25%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 11 de may
Actualizado: lun., 11 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
10.68%
Access Industries, Inc.
7.37%
RA Capital Management, LP
5.17%
BlackRock Institutional Trust Company, N.A.
5.03%
T. Rowe Price Associates, Inc.
4.37%
Otro
67.37%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
10.68%
Access Industries, Inc.
7.37%
RA Capital Management, LP
5.17%
BlackRock Institutional Trust Company, N.A.
5.03%
T. Rowe Price Associates, Inc.
4.37%
Otro
67.37%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
44.95%
Investment Advisor/Hedge Fund
23.12%
Hedge Fund
14.23%
Venture Capital
11.11%
Private Equity
8.25%
Corporation
7.37%
Research Firm
2.89%
Sovereign Wealth Fund
0.89%
Individual Investor
0.55%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
399
42.26M
110.63%
+1.07M
2025Q4
361
37.77M
100.05%
-1.81M
2025Q3
341
35.08M
92.93%
-3.22M
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
4.08M
10.69%
+142.59K
+3.62%
Dec 31, 2025
Access Industries, Inc.
2.81M
7.38%
-744.05K
-20.91%
Oct 20, 2025
RA Capital Management, LP
1.98M
5.18%
+399.03K
+25.30%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
5.04%
+227.96K
+13.45%
Dec 31, 2025
T. Rowe Price Associates, Inc.
1.67M
4.37%
+368.25K
+28.32%
Dec 31, 2025
Wellington Management Company, LLP
1.52M
3.98%
+108.20K
+7.67%
Dec 31, 2025
Atlas Venture
1.51M
3.97%
-628.74K
-29.34%
Dec 31, 2025
Fidelity Institutional Asset Management
1.29M
3.38%
+373.73K
+40.80%
Dec 31, 2025
Frazier Life Sciences Management, L.P.
1.26M
3.3%
-178.53K
-12.41%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ALPS Medical Breakthroughs ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.11%
JPMorgan Healthcare Leaders ETF
0.92%
State Street SPDR S&P Biotech ETF
0.79%
Direxion Daily S&P Biotech Bull 3X Shares
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.4%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.29%
iShares Health Innovation Active ETF
0.27%
iShares Biotechnology ETF
0.18%
Ver más
ALPS Medical Breakthroughs ETF
Proporción1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.11%
JPMorgan Healthcare Leaders ETF
Proporción0.92%
State Street SPDR S&P Biotech ETF
Proporción0.79%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.48%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.4%
ProShares Ultra Nasdaq Biotechnology
Proporción0.39%
Invesco Nasdaq Biotechnology ETF
Proporción0.29%
iShares Health Innovation Active ETF
Proporción0.27%
iShares Biotechnology ETF
Proporción0.18%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
